Two Drugs Approved for NPM1-Mutated Leukemia

(MedPage Today) — The FDA has approved two targeted menin inhibitors for the treatment of relapsed/refractory NPM1-mutated acute myeloid leukemia (AML).
Ziftomenib (Komzifti) was approved on Thursday for adults with relapsed/refractory NPM1-mutated…

Source link : https://www.medpagetoday.com/hematologyoncology/leukemia/118506

Author :

Publish date : 2025-11-13 19:16:00

Copyright for syndicated content belongs to the linked Source.

M	T	W	T	F	S	S
			1	2	3	4
5	6	7	8	9	10	11
12	13	14	15	16	17	18
19	20	21	22	23	24	25
26	27	28	29	30	31

Two Drugs Approved for NPM1-Mutated Leukemia

Second Menin Inhibitor Approved for Mutated R/R AML

RFK Jr. ‘Diss Track’; Med Student Qualifies for Olympic Trials; Infant Formula PSA

Related Posts

Trends in Skilled Nursing Facilities; Abortion Pill’s Regulatory History

Easing AI and Wearables Regulation Is a Risky Move

The Healthcare Debate Is Back in Washington. It Never Really Went Away.

First treaty to protect the high seas comes into force

Tylenol in Pregnancy Not Tied to Autism, Rigorous Review Shows

FDA Flags Boston Scientific Device Tied to 3 Deaths, Scores of Injuries

Trends in Skilled Nursing Facilities; Abortion Pill’s Regulatory History

Easing AI and Wearables Regulation Is a Risky Move

The Healthcare Debate Is Back in Washington. It Never Really Went Away.

First treaty to protect the high seas comes into force

Tylenol in Pregnancy Not Tied to Autism, Rigorous Review Shows

FDA Flags Boston Scientific Device Tied to 3 Deaths, Scores of Injuries

MedPAC Recommends Small Boost to Physician Pay, Though Some Say It’s a Pay Cut

UnitedHealth Upcoded Medicare Advantage Claims to Get More $$, Senate Report Says

Categories

Archives